RxDoctor Payments Data

John Passalaris, MD

Cardiovascular Disease · Princeton, NJNPI 1154351666

Payments from drug & device makers

$367in general payments, 2019–2025

Across 6 payments — averaging $61.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$131
  • Impulse Dynamics (USA) Inc.$130
  • Preventice Services, LLC$73
  • Pfizer$33

What the payments were for

  • Food & beverage$36298%
  • Education$62%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$367 in reported general payments places this provider in the 15th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$266,086
Medicare patients
1,325
Services billed
3,734

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban302$424,409
XareltoRivaroxaban74$96,619
EntrestoSacubitril/Valsartan13$16,920
Praluent PenAlirocumab18$16,752
BrilintaTicagrelor11$13,519
Carvedilol ErCarvedilol Phosphate13$7,616
Metoprolol Succinate476$7,510
Dofetilide18$5,081
Diltiazem 24hr Er (Cd)Diltiazem Hcl128$4,323
Nebivolol Hcl65$4,252
Atorvastatin Calcium357$4,051
Rosuvastatin Calcium211$3,682
Olmesartan Medoxomil104$2,771
PradaxaDabigatran Etexilate Mesylate11$2,076
Amlodipine Besylate290$2,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$424,409302 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Princeton

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →